Evolocumab
Evolocumab
Evolocumab (pronounced as e-vo-lo-cu-mab) is a monoclonal antibody designed for the treatment of hyperlipidemia. It is marketed under the trade name Repatha by Amgen.
Etymology
The name "Evolocumab" is derived from the International Nonproprietary Names (INN), where "Evo-" refers to evolution, "-lo-" is a placeholder, "-cu-" refers to cardiovascular, and "-mab" is typical for monoclonal antibodies.
Function
Evolocumab is a fully human monoclonal antibody that inhibits Proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets low-density lipoprotein receptors (LDLR) for degradation, thereby reducing the liver's ability to remove low-density lipoprotein (LDL), or "bad" cholesterol, from the blood. Evolocumab, by blocking PCSK9, increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.
Clinical Use
Evolocumab is used in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C; and in adult patients with homozygous familial hypercholesterolemia (HoFH) in combination with other lipid-lowering therapies.
Related Terms
- Monoclonal antibody
- Hyperlipidemia
- Proprotein convertase subtilisin/kexin type 9
- Low-density lipoprotein
- Low-density lipoprotein receptor
- Heterozygous familial hypercholesterolemia
- Homozygous familial hypercholesterolemia
- Atherosclerotic cardiovascular disease
External links
- Medical encyclopedia article on Evolocumab
- Wikipedia's article - Evolocumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski